Penumbra, Inc. (PEN) - Q2 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2026. Penumbra, Inc. is the world's leading thrombectomy company, focused on innovative technologies for ischemic stroke, venous thromboembolism, and acute limb ischemia. The company operates as a single segment, designing, manufacturing, and marketing medical devices globally.
Material Event: On January 14, 2026, Penumbra entered into a definitive merger agreement to be acquired by Boston Scientific Corporation. The transaction values Penumbra at approximately $14.5 billion enterprise value, with shareholders receiving $374 per share (73% cash, 27% stock). The merger is expected to close in 2026, subject to regulatory approvals.
Key Financial Metrics (Six Months Ended June 30, 2026)
| Metric | Value (in millions) | YoY Change |
|---|---|---|
| Revenue | $764.8 | +15.3% |
| Gross Profit | $518.4 | +17.8% |
| Gross Margin | 67.8% | +150 bps |
| Operating Income | $79.3 | -2.4% |
| Net Income | $67.4 | -20.2% |
| Diluted EPS | $1.70 | -21.4% |
| Operating Cash Flow | $133.1 | +41.7% |
| Cash & Marketable Investments | $658.8 | N/A |
| Working Capital | $1,110.3 | N/A |
Material Changes vs. Prior Period
- Revenue Growth: Driven by a 12.3% increase in Thrombectomy sales and a 21.8% increase in Embolization and Access sales. Growth was primarily volume-driven in the U.S. market.
- Expense Expansion: Sales, General, and Administrative (SG&A) expenses increased by 24.8% ($77.9 million) year-over-year. This was largely due to a $16.4 million increase in acquisition-related expenses (professional fees for the Boston Scientific merger) and increased personnel costs to support growth.
- Tax Rate Volatility: The effective tax rate rose to 23.3% from 5.2% in the prior year, primarily due to a decrease in excess tax benefits from stock-based compensation.
- Investing Activities: Net cash used in investing activities increased significantly to $121.7 million, driven by net purchases of marketable investments ($93.5 million) and capital expenditures of $27.2 million (including the Costa Rica facility).
Outlook, Risks, and Management Commentary
- Merger Status: The company is operating under the Merger Agreement with Boston Scientific. Termination fees are set at $525 million (payable by Penumbra) and $900 million (payable by Boston Scientific) under specific circumstances.
- Capital Allocation: The company maintains a share repurchase authorization with $100.0 million remaining authority as of June 30, 2026. No repurchases were made in the current quarter.
- Manufacturing Expansion: The company is constructing a new manufacturing facility and warehouse in Costa Rica. The total project cost estimate increased by approximately $28 million to roughly $88 million due to scope refinements.
- Risks: Key risks include the uncertainty of regulatory approval for the merger, foreign exchange fluctuations (21.3% of revenue is international), and the ability to successfully integrate with Boston Scientific post-closing.
Investor Verification Checklist
- Merger Closing Conditions: Verify the status of regulatory approvals required for the Boston Scientific acquisition and the likelihood of closing in 2026.
- Acquisition-Related Costs: Confirm the run-rate of professional fees and transaction costs associated with the merger to assess future earnings impact.
- Costa Rica Project: Review the updated budget and timeline for the new manufacturing facility to ensure capital expenditure forecasts remain accurate.
- Stock-Based Compensation: Monitor the impact of the merger on the vesting and conversion of outstanding RSUs and options, as detailed in the Merger Agreement.
- Liquidity Position: Verify the composition of the $658.8 million in cash and marketable investments to ensure sufficient liquidity for operations pending the merger close.